PowerPoint - Imperial College Faculty of Medicine
PowerPoint - Imperial College Faculty of Medicine
PowerPoint - Imperial College Faculty of Medicine
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Increasing use <strong>of</strong> risk-sharing agreements<br />
Particularly in oncology.<br />
• Different types <strong>of</strong> risk-sharing<br />
agreement are used:<br />
• Risk sharing (rebate) –<br />
reimbursement <strong>of</strong> drug cost for<br />
non-responders<br />
• Cost sharing (discount) –<br />
discounted drug price<br />
• Payment by results (rebate) –<br />
reimbursement <strong>of</strong> first cycles for<br />
non-responders<br />
• Avastin (in NSCLC, CRC, BC, RCC):<br />
50% reimbursed for the first three<br />
cycles; 100% reimbursed for cycles<br />
4–14; cost <strong>of</strong> subsequent cycles<br />
borne by manufacturer<br />
• Sutent (in mRCC): first course <strong>of</strong><br />
treatment is free<br />
• Torisel (in mRCC): total<br />
reimbursement limited to 8 packs<br />
(~2 months <strong>of</strong> therapy); additional<br />
cost is paid back by the manufacturer<br />
if the patient discontinues treatment<br />
during this period<br />
Page 18
Change language